Service Announcement

We are happy to announce that we can present price reductions on 9 medicines that are not yet available to patients and doctors globally for diseases like ovarian cancer, breast cancer and multiple sclerosis. As a social enterprise our commitment is to continuously find, negotiate and provide the lowest prices possible on every medicine that we offer.

There are also price increases on 3 medicines.

How do we do this?

  • We have a dedicated sourcing manager, Sera Gulser, who is dedicated to ensuring we increase accessibility by driving down prices as best we can.

  • We constantly seek new suppliers and new supplies of genuine newly-approved medicines. Additionally, our trusted suppliers also seek lower priced sources themselves.

Supplies of medicines change constantly and sometimes prices also increase. If you have any questions about a price of a medicine please Contact us.

Medicine

Price Change %

New Price

Spinraza (nusinersen) 2.4 mg/ml in 1 vial of 12mg/5ml

-8.41%

€99,000

Opdivo (nivolumab) 10 mg/ml in 1 vial of 4 ml

-7.67%

€540.50

Mavenclad (cladribine) 10 mg x 1 tablet

-4.05%

€2,612.80

Ibrance (palbociclib) 125 mg x 21 capsules

-13.9%

€4,594.25

Ibrance (palbociclib) 100 mg x 21 capsules

-13.90%

€4,594.25

Ibrance (palbociclib) 75 mg x 21 capsules

-13.90%

€4,594.25

Zejula (niraparib) 100 mg x 56 capsules

-2.01%

€8,395.00

Zejula (niraparib) 100 mg x 84 capsules

-0.46%

€12,420.00

Calcort (deflazacort) - 6 mg x 20 tablets

-13.51%

€11.44

Lynparza (olaparib) - 50 mg x 448 capsules

+6.59%

€6,619.40

Taltz (ixekizumab) - 80 mg x 2 syringes or pens

+7.84%

€2,750.80

Taltz (ixekizumab) - 80 mg x 3 syringes or pens

+8.87%

€4,134.25